|
Early palliative care prolonged survival and improved the quality of life (QOL) of patients with stage IV non-small cell lung cancer (NSCLC), according to Jennifer S. Temel, MD, of Massachusetts General Hospital, who presented study results during the June 7 Lung Cancer — Metastatic Oral Abstract Session (Abstract 7509).
|
The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) conducted a systematic review of medical research literature with Cancer Care Ontario to develop a joint guideline that will improve the accuracy of immunohistochemistry (IHC) testing for the expression status of estrogen (ER) and progesterone receptors (PgR) in breast cancer.
|
A randomized phase III trial found that a regimen of 5-fluorouracil (5FU)/leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) resulted in substantially better response rates, progression-free survival (PFS), and overall survival (OS) for patients with metastatic pancreatic adenocarcinoma, compared with gemcitabine, as presented by Thierry Conroy, MD, of the Centre Alexis Vautrin, France, during the June 7 Gastrointestinal (Noncolorectal) Cancer Oral Abstract Session (Abstract 4010).
|
Given alone, vandetanib increases progression-free survival (PFS) in patients with locally advanced or metastatic medullary thyroid cancer (MTC), based on a study reported during the June 7 Head and Neck Cancer Oral Abstract Session (Abstract 5503).
|
Gene expression studies presented during the Tumor Biology Oral Abstract Session on June 7 highlighted progress that has been made in the understanding of the biology of cancer and how it might be treated on a molecular level.
|
Three studies presented during the Breast Cancer — Metastatic Oral Abstract Session on June 8, provided evidence that estrogen receptor (ER), progesterone receptor (PgR), and HER2 status is frequently different in primary breast tumors compared with subsequent locoregional recurrences and distant metastasis.
|
A multicenter, randomized, phase III trial of patients with esophageal or esophagogastric junction cancer found that preoperative chemoradiotherapy with paclitaxel and carboplatin resulted in better overall survival than surgery alone.
|
A phase II trial examining the use of oral capecitabine and cyclophosphamide for the treatment of women with metastatic breast cancer has shown that the combination compares favorably with capecitabine alone, or capecitabine and bevacizumab or sorafenib, especially for pretreated, estrogen receptor (ER)-negative disease.
|
Partial results from a terminated phase III trial of adjuvant paclitaxel, gemcitabine, and cisplatin (PGC) suggest that the triplet may improve overall survival (OS), progression-free survival (PFS), time to progression (TTP), and disease-specific survival (DSS) for patients with resected high-risk myoinvasive bladder cancer.
|
Cancer treatment will increasingly rely on molecular profiling of patients and tumors, and the next generation of genomic sequencing will produce vast amounts of information that will require new systems for handling and retrieving the data. These were among the predictions of experts in the field of cancer genomics speaking at the Special Session, “From the Cancer Genome to Patients with Cancer: The Next Generation of Innovation — An ASCO/ American Association for Cancer Research (AACR) Joint Session,” on June 7.
|
|
|
